Showing 421 - 440 results of 5,256 for search 'x86~', query time: 1.35s Refine Results
  1. 421

    All About Animals by Deborah J. Glauer, Joy Cantrell

    Published 2002-10-01
    Subjects: “…4H106…”
    Get full text
    Article
  2. 422

    Unlock Your Leadership Potential Leader's Guide by John Rutledge, Lori Spivey

    Published 2002-11-01
    Subjects: “…4H181…”
    Get full text
    Article
  3. 423
  4. 424

    Clothing Capers Workbook by Joy Cantrell Jordan, R. Nadine Hackler

    Published 2002-11-01
    Subjects: “…4H116…”
    Get full text
    Article
  5. 425
  6. 426

    Keamanan Data Menggunakan Secure Hashing Algorithm (SHA)-256 dan Rivest Shamir Adleman (RSA) pada Digital Signature by Juniar Hutagalung, Puji Sari Ramadhan, Sarah Juliana Sihombing

    Published 2023-12-01
    “…Setelah menggunakan metode SHA-256 dan RSA, hasil akhir adalah "09C6423CF09C9E61BC09B29966DE6CB569A7DE2C4349FA2B52F 08EF39D07140F". …”
    Get full text
    Article
  7. 427
  8. 428

    CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1–CXCR2 induced NETs by Yu Liang, Shuang Chen, Zhi Chen, Fang Peng, Qianwen Liu, Gan Xiong, Caihua Zhang, Maosheng Cheng, Rongsong Ling, Demeng Chen, Qimin Zhou

    Published 2024-05-01
    “…Furthermore, we used the 4NQO-induced mouse model to evaluate the effects of anti-CXCL1 antibodies, anti-Ly6G antibodies, anti-NK1.1 antibodies, and GSK484 inhibitors on tumor growth. …”
    Get full text
    Article
  9. 429
  10. 430

    Risk factors of 180-day rebleeding after management of blunt splenic injury without surgery and embolization: a national database study by Chung-Yen Chen, Hung-Yu Lin, Pie-Wen Hsieh, Yi-Kai Huang, Po-Chin Yu, Jian-Han Chen

    Published 2025-02-01
    “…Patients with > 2 points had significantly higher rebleeding rates (risk-identifying cohort: 2.2% vs. 0.6%, OR 3.790, p < 0.001; validation cohort: 2.6% vs. 0.8%, OR 3.129, p = 0.022). …”
    Get full text
    Article
  11. 431
  12. 432
  13. 433
  14. 434
  15. 435
  16. 436

    miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting by Yilan Xu, Danyang Li, Na Wang, Bei Ge, Chen Meng, Min Zhao, Zihan Lin, Min Li, Yigang Yuan, Yue Cai, Liuzhi Shi, Shenmeng Gao, Haige Ye

    Published 2025-02-01
    “…Finally, the area under the curve (AUC) for 1-year mortality was 0.831, for 2-year was 0.788, and for 3-year was 0.800. Conclusions AML patients with miR-182 promoter hypermethylation have better outcomes. miR-182 promoter methylation is a predictive biomarker for AZA + VEN-treated AML patients.…”
    Get full text
    Article
  17. 437
  18. 438
  19. 439
  20. 440